Fiszer Marta, Kołaciński Zbigniew, Rechciński Tomasz
Klinika Ostrych Zatruć, Instytut Medycyny Pracy.
Przegl Lek. 2007;64(4-5):293-7.
Calcium channel inhibitors have been extensively used to treat arterial hypertension, ischaemic heart disease and supraventricular rhythm irregularities. The poisonings by that category of drugs are extremely dangerous, particularly when accompanied by intoxication with other drugs affecting the circulatory function. This paper reports 3 cases of poisonings with calcium channel inhibitors (verapamil and diltiazem) in combination with angiotensin convertase inhibitors and nonselective beta-adrenolytics. Circulatory insufficiency and cardiac rhythm abnormalities were noted in all reported cases, in one in the form of ventricular bigeminy and two episodes of ventricular fibrillation, while in the two other cases in the form of 1 degree atrioventricular block. The persisting hypotonia combined with heart rhythm disturbances could not be prevented by the typical conservative treatment involving intravenous administration of infusion fluids, calcium formulations, catecholamines and atropin. The application of 4-amino-pyridine (Pymadin) caused that arterial tension and heart rate were higher, and the heart rhythm disturbances disappeared. The reported cases suggest a beneficial effect of 4-aminopyridine used to treat cases of poisonings by calcium channel inhibitors; however, up to the present time, no detailed procedures have been determined for 4-aminopyridine administration in cases like those reported above. 4-aminopyridine has not been included in the list of the antidotes approved by the WHO and, therefore, broader tests and more clinical observations are required to confirm its therapeutic value.
钙通道抑制剂已被广泛用于治疗动脉高血压、缺血性心脏病和室上性心律失常。这类药物中毒极其危险,尤其是伴有影响循环功能的其他药物中毒时。本文报告了3例钙通道抑制剂(维拉帕米和地尔硫䓬)与血管紧张素转换酶抑制剂及非选择性β-肾上腺素能阻滞剂联合中毒的病例。所有报告病例均出现循环功能不全和心律失常,1例表现为室性二联律和2次室颤发作,另外2例表现为一度房室传导阻滞。通过静脉输注液体、钙剂、儿茶酚胺和阿托品进行的典型保守治疗无法预防持续的低血压合并心律紊乱。应用4-氨基吡啶(匹吗啉)后,动脉血压和心率升高,心律紊乱消失。报告的病例表明4-氨基吡啶对治疗钙通道抑制剂中毒病例有有益作用;然而,目前尚未确定在上述病例中使用4-氨基吡啶的详细程序。4-氨基吡啶未被列入世界卫生组织批准的解毒剂清单,因此,需要更广泛的试验和更多的临床观察来证实其治疗价值。